AccessibilityHelpAbout Us
9 Meters Biopharma logo

9 Meters Biopharma(OTC) NMTRQ

Market Cap$1.40KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-100%
5 Year-100%
1 Year+9,900%
1 Month+9,900%
$0.00
+0.00%
+0.00Today
9 Meters Biopharma last closing stock price
MetricPriceDate
Last closeUSD 0.002026-09-17
9 Meters Biopharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+9,900%USD 0.002026-09-10
1 month+9,900%USD 0.002026-08-17
3 month+9,900%USD 0.002026-06-16
Year to date+9,900%USD 0.002025-12-31
1 year+9,900%USD 0.002025-09-17
3 year-99.23%USD 0.012023-09-18
5 year-100%USD 24.202021-09-17
Since inception-100%USD 116.002018-01-31

9 Meters Biopharma Financials at a Glance

Market Cap

$1.40KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

N/A

Net Income (TTM)

N/A

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-89.28 (Low)

Price

$0.00

Volume

694

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Aug 31, 2026

NMTRQ News

GettyImages-943401146

Why 9 Meters Biopharma Stock Is Soaring Today

Prosper Junior BakinyApr 7, 2021
Getty-stock-market-data2

Why Blue Apron, Tribune Media, and Innovate Biopharmaceuticals Slumped Today

Steve SymingtonJul 16, 2018
Businessman looking at falling line chart

Why Innovate Biopharmaceuticals Stock Cratered Today

Keith SpeightsJul 16, 2018
Man behind stock chart

3 Biotech Stocks That Soared This Week: Are They Buys?

Keith SpeightsJun 30, 2018

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About 9 Meters Biopharma

9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical firm focused on developing therapies for rare digestive illnesses and gastrointestinal disorders. The company is headquartered in Raleigh, North Carolina, and is dedicated to addressing unmet medical needs through innovative treatments.

Products and Services
  • Vurolenatide: A long-acting injectable for short bowel syndrome
  • NM-136: A humanized monoclonal antibody targeting obesity
  • NM-003: A glucagon-like peptide-2 receptor agonist for acute graft versus host disease
Growth Outlook
  • Pipeline includes multiple candidates in various stages of clinical trials
  • Partnerships with established firms enhance research capabilities
  • Focus on rare diseases positions the company in a niche market
Financial Highlights
  • Market capitalization stands at approximately $1.45 million
  • Stock price has fluctuated between $0.00001 and $0.0005 over the year
  • Recent trading volume indicates active investor interest
9 Meters Biopharma, Inc. operates in the biotechnology sector, specializing in innovative treatments for conditions that currently lack effective therapies. The company's lead candidate, Vurolenatide, is in Phase 3 trials, showcasing its commitment to advancing drug development. The focus on rare diseases and gastrointestinal disorders presents a unique opportunity in a market with significant unmet needs. Partnerships with other firms further strengthen the company's research and development efforts, potentially accelerating the path to market for its therapies. Despite recent challenges, including a voluntary petition for liquidation, the company remains a point of interest for investors monitoring the biotechnology landscape.
AI Generated • Sep 11, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

10

CEO

John Temperato

Website

9meters.com

Headquarters

Raleigh, NC 27612, US

NMTRQ Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$1.40KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

14.46M

Volume

694

Avg. Volume

290.603

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

9 Meters Biopharma Performance Analysis

9 Meters Biopharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 0N/A
20222022-12-31USD 0N/A
9 Meters Biopharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -3.03N/A
20222022-12-31USD -3.3811.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
CurrentYOY CHG

Revenue

N/A

N/A

Gross Profit

N/A

N/A

Gross Margin

N/A

N/A

Market Cap

$1.40KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

N/A

N/A

EBITDA

N/A

N/A

Quarterly Fundamentals

Name
CurrentYOY CHG

Total Cash

N/A

N/A

Total Debt

N/A

N/A

Accounts Receivable

N/A

N/A

Inventory

N/A

N/A

Long Term Debt

N/A

N/A

Short Term Debt

N/A

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

N/A

N/A

Operating Cash Flow

N/A

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BRSFBrain Scientific Inc.
$0.00+0.00%
GMVDFG Medical Innovations Holdings Ltd
$0.00+0.00%
INLBItem 9 Labs Corp.
$0.00+0.00%
CEROCERo Therapeutics Holdings, Inc.
$0.01+3.77%

Trending Stocks

Symbol / CompanyPricePrice Chg
WBDWarner Bros. Discovery
$30.80+10.79%
GRMLGreenland Mines
$9.42+230.53%
INTCIntel
$121.78+12.14%
NVDANvidia
$227.38+2.30%

Questions About NMTRQ

What is the current price of 9 Meters Biopharma?

9 Meters Biopharma is trading at $0.00 per share.

What is the 52-week range for 9 Meters Biopharma?

Over the past 52 weeks, 9 Meters Biopharma has traded between $0.00 and $0.00.

How much debt does 9 Meters Biopharma have?

As of the most recent reporting period, 9 Meters Biopharma reported total debt of $19.73M.

How much cash does 9 Meters Biopharma have on hand?

9 Meters Biopharma reported $29.66M in cash and cash equivalents in its most recent financial results.

What is 9 Meters Biopharma’s dividend yield?

9 Meters Biopharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services